• Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline

    1 month ago - By Precision Biosciences

    Accelerated Clinical Development Expected to Enable Three Investigational New Drug/Clinical Trial Applications Within Next Three Years, Including for Familial Hypercholesterolemia as early as 2022, Primary Hyperoxaluria Type 1 in 2023, and Chronic Hepatitis B in 2024 - Announced Licensing and
    Read more ...

     

  • Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

    1 month ago - By Precision Biosciences

    DURHAM, N.C. --Sep. 10, 2021- Precision BioSciences, Inc. , a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will present at the H.C.
    Read more ...

     

  • Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic, Off-the-Shelf CD19-Targeting CAR-T Product, in Relapsed/Refractory CD19+ NHL

    1 month ago - By Precision Biosciences

    Shah, B.D. et al. American Society of Clinical Oncology 2021 Annual Meeting.
    Read more ...

     

  • Precision BioSciences Appoints Michael Amoroso Chief Executive Officer

    1 month ago - By Precision Biosciences

    DURHAM, N.C. --Sep. 27, 2021- Precision BioSciences, Inc. , a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Michael Amoroso has been named as the
    Read more ...

     

  • Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(4)

    1 month ago - By Precision Biosciences

    DURHAM, N.C. --Sep. 27, 2021- Precision BioSciences, Inc. , a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced an inducement grant for Michael Amoroso , newly
    Read more ...

     

  • Precision BioSciences Statement on Safety of its Allogeneic CAR T Cells

    1 month ago - By Precision Biosciences

    Precision BioSciences, Inc. , a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, issued the following statement about the safety of its allogeneic CAR T cell therapies.
    Read more ...